$90m IPO Sets Up Sweden's Calliditas For Phase III Readout
Biotech Sector Listings Defying Pandemic
The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.
You may also be interested in...
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.
Key committee was asked to fast-track a decision on the antibody cocktail, but lack of mortality data could mean patchy uptake seen in US repeated in the EU.